| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
|
| | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane Basic information |
| Product Name: | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane | | Synonyms: | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane;1-(3-O-sulfo-beta-D-galactosyl)-N-tetracosanoylsphingosine;C24 3'-sulfo Galactosylceramide (d18:1/24:0);C24 3’-sulfo Galactosylceramide (d18:1/24:0);Tetracosanamide, N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]-;N-Tetracosanoyl-sulfatide;N-Tetracosanoyl sulfatide, CNS sulfolipid analogue | | CAS: | 151122-71-3 | | MF: | C48H93NO11S | | MW: | 892.32 | | EINECS: | | | Product Categories: | | | Mol File: | 151122-71-3.mol | ![(2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane Structure](CAS/GIF/151122-71-3.gif) |
| | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane Chemical Properties |
| density | 1.09±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Chloroform:Methanol (5:1): soluble | | form | A solid | | pka | -3.61±0.18(Predicted) |
| | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane Usage And Synthesis |
| Uses | Tetracosanoyl-sulfatide is an endogenous metabolite present in Urine that can be used for the research of Mild Metachromatic Leukodystrophy[1][2]. | | Definition | ChEBI: A D-galactosyl-N-acylsphingosine having a sulfo group at the 3-position on the galactose ring and tetracosanoyl as the N-acyl group. | | References | [1] Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. DOI:10.1038/s41388-020-01395-9 [2] Natowicz MR, et al. Urine sulfatides and the diagnosis of metachromatic leukodystrophy. Clin Chem. 1996 Feb;42(2):232-8. PMID:8595716 |
| | (2R,3S,4S,5R,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2S,3R)-3-hydrox y-2-(tetracosanoylamino)octadec-4-enoxy]-4-sulfooxy-oxane Preparation Products And Raw materials |
|